Travere Therapeutics, Inc.

Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases. The company develops and commercializes therapies targeting patient populations with limited treatment options. Its marketed products include FILSPARI (sparsentan), a once-daily oral medication for IgA Nephropathy that targets endothelin-1 and angiotensin-II pathways, and Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder characterized by elevated urinary cystine levels and recurrent kidney stone formation.

The company maintains a clinical-stage pipeline addressing underserved rare disease indications. Sparsentan is in development for focal segmental glomerulosclerosis, with Orphan Drug Designation granted in the United States and Europe. Pegtibatinase, a human enzyme replacement therapy candidate, is being evaluated for classical homocystinuria treatment. Travere also collaborates with PharmaKrysto Limited on preclinical activities related to its cystinuria program.

Based in San Diego, California, Travere operates with approximately 497 full-time employees. The company is listed on Nasdaq and holds a market capitalization of $2.7 billion. Its operations are primarily centered in the United States, where it markets approved therapies and advances its clinical development programs for rare metabolic and glomerular diseases.